Development of budesonide nanocluster dry powder aerosols: Preformulation

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3434-3444

  El Gendy, Nashwa ^a,c   Selvam, Parthiban ^a   Soni, Pravin ^d   Berkland, Cory ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c Beni Suef University   (Egypt)

^d PharMacro   (United States)

Author keywords

Aerosols; Attrition; Budesonide; Excipients; Formulation; Inhalation; NanoClusters; Nanoparticles; Nanotechnology; Pulmonary drug delivery

Indexed keywords

ALCOHOL; BUDESONIDE; EXCIPIENT; LACTOSE; NANOPARTICLE; POLOXAMER; SODIUM CHLORIDE;

AEROSOL; ARTICLE; IONIC STRENGTH; PARTICLE SIZE; SURFACE TENSION;

EID: 84864040393     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23197     Document Type: Article

References (40)

1. Smyth HDC, Hickey AJ. 2005. Carriers in drug powder delivery: Implications for inhalation system design. Am J Drug Deliv 3(2):117-132.
2. Timsina M, Martin G, Marriott C, Ganderton D, Yianneskis M. 1994. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 101(1-2):1-13.
3. Bosquillon C, Lombry C, Preat V, Vanbever R. 2001. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 70(3):329-339.
4. Jones MD, Harris H, Hooton JC, Shur J, King GS, Mathoulin CA, Nichol K, Smith TL, Dawson ML, Ferrie AR. 2008. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur J Pharm Biopharm 69(2):496-507.
5. Jones MD, Price R. 2006. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res 23(8):1665-1674.
6. Adi H, Larson I, Chiou H, Young P, Traini D, Stewart P. 2006. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm Res 23(11)2556-2565.
7. Chan HK. 2006. Dry powder aerosol delivery systems: Current and future research directions. J Aerosol Med 19(1):21-27.
8. Frijlink H, De Boer A. 2004. Dry powder inhalers for pulmonary drug delivery. Exp Opin Drug Deliv 1(1):67-86.
9. Lechuga-Ballesteros D, Charan C, Stults CLM, Stevenson CL, Miller DP, Vehring R, Tep V, Kuo MC. 2008. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97(1):287-302.
10. Seville PC, Learoyd TP, Li HY, Williamson I, Birchall JC. 2007. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 178(1):40-50.
11. Pilcer G, Amighi K. 2010. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392(1):1-19.
12. Selvam P, Bharatwaj B, Porcar L, da Rocha SRP. 2011. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics. Int J Pharm 422(1-2):428-435.
13. Meakin BJ, Lewis DA, Berrill SA, Davies RJ. 2006. Solubilisation of drugs in HFA propellant by means of emulsions. Italy. Patent EP1369113 B1.
14. Chokshi U, Selvam P, Porcar L, da Rocha SRP. 2009. Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. Int J Pharm 369(1-2):176-184.
15. Jones G, Ray WA. 1941. The surface tension of solutions of electrolytes as a function of the concentration. III. Sodium chloride. J Am Chem Soc 63(12):3262-3263.
16. Vazquez G, Alvarez E, Navaza JM. 1995. Surface tension of alcohol water + water from 20 to 50. degree. C. J Chem Eng Data 40(3):611-614.
17. Desai P, Jain N, Sharma R, Bahadur P. 2001. Effect of additives on the micellization of PEO/PPO/PEO block copolymer F127 in aqueous solution. Colloids Surf A Physicochem Eng Asp 178(1-3):57-69.
18. Zeng XM, Pandhal KH, Martin GP. 2000. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm 197(1):41-52.
19. Louey MD, Stewart PJ. 2002. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 19(10):1524-1531.
20. Li HY, Seville PC, Williamson I, Birchall J. 2005. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 7(3):343-353.
21. Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E, Conway JH, Carroll MP, Shute JK, Smith JR. 2008. Cospray-dried unfractionated heparin with l-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci 97(11):4857-4868.
22. Brantley SL, Mellott NP. 2000. Surface area and porosity of primary silicate minerals. Am Mineralogist 85(11-12):1767-1783.
23. Bailey MM, Gorman EM, Munson EJ, Berkland C. 2008. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 24(23):13614-13620.
24. Gao L, Zhang D, Chen M. 2008. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanoparticle Res 10(5):845-862.
25. Lakshmi P, Ashwini K. 2010. Nanosuspension technology: A review. Int J Pharm Sci 2:35-40.
26. Yang W, Johnston KP, Williams III RO. 2010. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 75(1):33-41.
27. Patravale V, Date AA, Kulkarni R. 2004. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 56(7):827-840.
28. Peltonen L, Hirvonen J. 2010. Pharmaceutical nanocrystals by nanomilling: Critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol 62(11):1569-1579.
29. Verma S, Kumar S, Gokhale R, Burgess DJ. 2010. Physical stability of nanosuspensions: Investigation of the role of stabilizers on Ostwald ripening. Int J Pharm 406(1-2):1445-1152.
30. Aveyard R, Binks B, Chen J, Esquena J, Fletcher P, Buscall R, Davies S. 1998. Surface and colloid chemistry of systems containing pure sugar surfactant. Langmuir 14(17):4699-4709.
31. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113-120.
32. Kumar PV, Jain NK. 2007. Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles. AAPS PharmSciTech 8(1):118-123.
33. Islam N, Stewart P, Larson I, Hartley P. 2004. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 93(4):1030-1038.
34. Young PM, Chan H, Chiou H, Edge S, Tee THS, Traini D. 2007. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci 96(5):1331-1341.
35. Zeng XM, Martin GP, Tee SK, Marriott C. 1998. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int J Pharm 176(1):99-110.
36. Lucas P, Anderson K, Staniforth JN. 1998. Protein deposition from dry powder inhalers: Fine particle multiplets as performance modifiers. Pharm Res 15(4):562-569.
37. El-Gendy N, Gorman EM, Munson EJ, Berkland C. 2009. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 98(8):2731-2746.
38. Young P, Cocconi D, Colombo P, Bettini R, Price R, Steele D, Tobyn M. 2002. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing." J Pharm Pharmacol 54(10):1339-1344.
39. El-Gendy N, Desai V, Berkland C. 2010. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J Pharm Innov 5(3):79-87.
40. Thalberg K, Lindholm D, Axelsson A. 2004. Comparison of different flowability tests for powders for inhalation. Powder Technol 146(3):206-213.